The Impact of Age on the Efficacy of 13-valent Pneumococcal Conjugate Vaccine in Elderly.
In a post hoc analysis of the Community-Acquired Pneumonia (CAP) immunization Trial in Adults the model-predicted 13-valent pneumococcal conjugate vaccine efficacy for preventing vaccine-type specific CAP and Invasive Pneumococcal Disease declined from 65% to 40% for subjects being 65 and 75 year olds at the time of vaccination, respectively.
Julius Center for Health Sciences and Primary Care.
Cornelis H
CH
van Werkhoven
Julius Center for Health Sciences and Primary Care Department of Pulmonary Medicine.
Susanne M
SM
Huijts
Julius Center for Health Sciences and Primary Care.
Marieke
M
Bolkenbaas
Julius Center for Health Sciences and Primary Care.
Diederick E
DE
Grobbee
Julius Center for Health Sciences and Primary Care Department of Medical Microbiology, University Medical Center Utrecht, The Netherlands.
Marc J M
MJ
Bonten
D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D011008:Pneumococcal Infections / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000008:administration & dosage* / Q000276:immunology*; D016896:Treatment Outcome
C538862:13-valent pneumococcal vaccine; D022242:Pneumococcal Vaccines
community-acquired pneumonia; immunosenescence; invasive pneumococcal disease; pneumococcal conjugate vaccine; vaccine efficacy